Author: Aya Ragaai
Gennvax is advancing its strategic partnership with Kenya’s Ministry of Health, with the completion of a Memorandum of Understanding (MOU) currently in process. This collaboration focuses on enhancing vaccine access, supporting national health priorities, and moving toward self-sufficiency in vaccine production.
In addition to its health initiatives, Gennvax proudly sponsored Kenya’s Ministry of Health National Day on October 6th, supporting environmental sustainability and community engagement. In collaboration with Dr. Mary Muthoni Muriuki, Principal Secretary, State Department for Public Health and Professional Standards, Gennvax planted 200 trees and engaged local schools in campaigns to raise awareness about the environmental and societal benefits of tree planting.
This initiative reflects Gennvax’s broader commitment to:
• Integrating health and environmental responsibility by promoting green initiatives alongside public health programs.
• Community engagement and education, fostering awareness among students and local communities about climate change and sustainable practices.
• Partnership with government and educational institutions to support public health, environmental stewardship, and capacity-building initiatives.
• Long-term impact monitoring, including tracking the growth and survival of planted trees and linking these activities to local health and environmental outcomes.

Through these efforts, Gennvax continues to demonstrate its commitment to sustainable development, health equity, and community empowerment across Kenya and the broader African region.
Gennvax management held a high-level meeting with the Ministry of Science and Innovation of Uganda to discuss strategic collaboration in research and development.
The discussions focused on key partnership pillars, including:
• Upgrading laboratory infrastructure to support cutting-edge vaccine research.
• Conducting clinical trials for next-generation vaccines to ensure high readiness for outbreak response.
• Strengthening quality assurance through technical training and capacity-building initiatives
Gennvax management and team held a high-level meeting with the Ministry of Health of Uganda, including Hon. Margaret Muhanga Mugisa, Minister of State for Primary Health Care, and Hon. Anifa Kawooya Bangirana, Minister of State for Health in charge of General Duties.
During the meeting, both parties agreed to sign a Memorandum of Understanding (MOU) to formalize prospective collaboration. Gennvax also received an official letter of expression of support from the Ministry, marking a significant milestone in their partnership.
The collaboration aims to:
• Facilitate access to vaccines within Gennvax’s portfolio to address Uganda’s national health needs.
• Support technical training and knowledge exchange for Ugandan health professionals.
• Explore opportunities for local capacity building, including technology transfer and infrastructure development.

This initiative reflects Gennvax’s ongoing commitment to enhancing vaccine access, strengthening healthcare systems, and fostering regional collaboration across Africa.
Gennvax, Egypt’s pioneering vaccine manufacturing site, is dedicated to achieving self-sufficiency in core vaccines and contributing to Africa’s health security. In alignment with its vision to locally produce a significant share of the continent’s vaccine needs, Gennvax has embarked on its journey toward market access across Africa.
As a proud member of the Egyptian Vaccines Manufacturers Association (EVMA), Gennvax embraces its role in fostering regional collaboration and strengthening Africa’s biomanufacturing ecosystem. The company’s first destination on this strategic journey was Zimbabwe, where it received full support from Egypt’s Ministry of Foreign Affairs and the Egyptian Ambassador to Zimbabwe.
During a high-level meeting with Zimbabwe’s Ministry of Health and Child Care, Gennvax was honored to sign an Expression of Interest (EOI) with the Honorable Dr. Douglas Mombeshora, Minister of Health.
This agreement marks the beginning of a collaborative partnership aimed at:
• Facilitating access to vaccines within Gennvax’s portfolio to address Zimbabwe’s national health needs.
• Supporting technical training and knowledge exchange for Zimbabwean health professionals.
• Exploring opportunities for local capacity building, including potential technology transfer.
• Strengthening regulatory and quality assurance capabilities in vaccine evaluation and monitoring.
This milestone reflects Gennvax’s commitment to advancing vaccine equity, promoting regional self-reliance, and contributing to a healthier, more resilient Africa.
High-level meeting with Zimbabwe’s Ministry of Health and Child Care, Gennvax was honored to sign an Expression of Interest (EOI) with the Honorable Dr. Douglas Mombeshora, Minister of Health
As part of its commitment to strengthening regulatory partnerships across Africa, Gennvax held a high-level meeting with the Medicines Control Authority of Zimbabwe (MCAZ), represented by Dr. Zivanai Makoni, Head of the Evaluation and Registration Division.
During this strategic meeting, both parties agreed to initiate a pilot program that positions Egypt and Gennvax as the first collaborators to begin the vaccine registration submission process through the newly established MCAZ online platform.
Gennvax has officially received the first access link to commence the upload of its registration and evaluation files — a significant step toward accelerating the availability of quality-assured vaccines in the Zimbabwean market.
This collaboration reflects Gennvax’s ongoing efforts to enhance regulatory cooperation, streamline vaccine registration processes, and reinforce its role as a trusted African manufacturer committed to supporting health security and innovation across the continent.
“The Egyptian Ambassador to Zimbabwe / Hala Serag El Din and the entire embassy team extended their full support to our national project, reflecting the strong spirit of collaboration and shared commitment between Egypt and Zimbabwe toward advancing health and vaccine self-sufficiency across Africa,” said Gennvax representatives.

NAT Pharm Collaborates with Gennvax on Strategic Initiatives NatT Pharm, the leading procurement partner for Zimbabwean health authorities, along with its Managing Director, Newman B. Madzikwa, has formally agreed to collaborate with Gennvax on this strategic initiative. This partnership underscores a shared commitment to enhancing vaccine access, supporting local health systems, and strengthening regional healthcare capabilities.
The El Daba Holding CEO explains why he’s building where others hesitate, from biotech to real estate — and what legacy really means in business today
At first glance, Adam El-Daba could be mistaken for a textbook high-growth entrepreneur – CEO of El Daba Holding, founder of Gennecs Pharmaceuticals, principal investor in Gennvax, and angel backer of over 18 companies across five countries. But beneath the bullet points is a deeper motivation. For El-Daba, business has never been about following the market– it’s about serving the moment. It’s about identifying overlooked needs and delivering real-world solutions with precision, empathy, and scale.
“If there’s a common thread behind everything I do, it’s impact – paired with timing,” he says. “I’m drawn to ventures where I can help build something that moves people’s lives forward, whether that’s through housing, nutrition, or healthcare access. But timing is crucial.”
That instinct has enabled him to thrive across sectors most investors steer away from. It’s a strategy that puts him in spaces where complexity reigns – systems. “Most investors avoid them because of the complexity or long ROI cycles. That’s exactly why I lean in. I’m comfortable with complexity – and I’m not afraid of building where others hesitate, especially if the need is urgent and the impact is real.”
The vaccine gap that sparked a movement
El-Daba’s foray into healthcare wasn’t born from market analysis or sectoral trend reports – it was born from a visceral, emotional reaction to a problem most global investors overlook. “What opened my eyes – and frankly shocked me – was discovering that Africa needs over 1.3 billion vaccine doses each year, yet receives no more than 60–70 per cent of that,” he explains. “Imagine how many children are denied a fair, healthy start in life because of that gap.”
Then came the statistic that changed everything: 99.9 per cent of Africa’s vaccines are imported. “I knew I couldn’t look away. I invested time, energy, and capital to understand why this gap exists – and how we could help close it.”
That commitment became the blueprint for Gennecs and Gennvax – one focused on affordable therapeutics, the other on full-cycle vaccine production. “We’re not just another pharmaceutical company. We’re an answer to a deeply entrenched problem.” Gennvax is now building one of Africa’s first end-to-end vaccine manufacturing facilities in Egypt – designed to meet both local and continental demand, while reducing dependence on imports.
“Our edge lies in blending world-class R&D and regulatory standards with local insight and speed. We’re not trying to replicate someone else’s model –we’re building a new one, tailored for the Middle East and Africa, with global partnerships, WHO alignment, and an unapologetic focus on access and equity.”
But El-Daba is quick to point out that such a bold undertaking is not a solo act. “Of course, none of this would be possible without our partners. Their belief, support, and technical expertise are the engine behind the mission. Together, we’re proving that Africa doesn’t have to wait in line for innovation– we can lead.”
El-Daba’s reputation as an angel investor is well-earned, but his thesis is different from the norm. “To be honest, I don’t invest in ideas – I invest in people. And not just any people – the kind who are ready for the rollercoaster, not just the highlight reel.”
What he seeks in founders is not polish or pedigree but resilience, clarity, and shared purpose. “In every company I’m involved with, the founders aren’t just colleagues – they’re family. And the flavor that makes the whole dish come together? That’s the rest of the team, who I also consider family. Everyone brings their own spice, and if the kitchen’s working, you’ve got a recipe for something special.”
“I’m hands-on, but not hovering. I empower my teams as much as possible, but I’m also not afraid to dive deep into the details. Whether it’s biotech, commodities, or tech, I make it a point to understand the technical side – not just the business case.”
His own origin story as a founder reflects this ethos. “Back in my early 20s, I was working for a company in Toronto… great salary, great growth. Then I made what most people would call a ridiculous decision: I quit. No real-world that I wanted to build something of my own.”
“The first couple of apps we built were total flops. I still remember the sting– but I also remember how we kept going. And eventually, one of those risks turned into a company that changed everything.”
“Sometimes the worst decisions on paper are the ones that shape your future the most.”
Building institutions that outlast the founder
What sets El-Daba apart isn’t just scale or diversification, but his systems thinking. “Leadership isn’t one-size-fits-all – it’s more like tailoring a suit to fit each team. But one rule holds everywhere: people matter most. I lead with clarity and empathy, and I listen – even when I already have an answer. The biggest lesson I’ve learned across sectors? Collaboration beats control. The best ideas often come from where you least expect them – if you’re open enough to hear them.”
At El Daba Holding, this mindset manifests in multi-sector growth anchored in local relevance. “I try not to focus too much on the role we want to play –instead, I focus on the steps we can take today to make a small, meaningful difference.”
The healthcare vertical has become one of the most defining. “If what we’re doing gives just one investor the confidence to bet on this region, then we’ve already made a dent.”
El-Daba sees legacy through a personal lens. “The immediate definition that comes to mind is: my father. If you truly want to understand legacy – not just as a word, but as a living example – then he’s the blueprint. I might be biased(or definitely am), but anyone who knows him and is reading this will agree without hesitation.”
“Legacy isn’t just about what people say after you’re gone – it’s about the quiet respect, admiration, and impact you carry while you’re still here.”
Off the pitch, on point
When El-Daba isn’t launching healthcare ventures or scaling region-wide operations, he’s either mentoring future founders or playing football. And for him, the two aren’t so different.
“Football, for me, isn’t just a sport – it’s a leadership masterclass in disguise. It teaches you how to trust your team, adapt your strategy on the fly, and most importantly, how to stop chasing the ball and start reading the game.”
I’m more of the player-coach guiding the team to reach their full potential, making sure no one’s afraid to try, fail, or learn.”
“If you’re afraid to shoot, you’ll never score (and yes, I’ve defi nitely missed afew open goals myself).”
Philanthropy, mentorship, and sport are not sidelines – they are how he tests ideas, builds community, and stays grounded. “I always walk in thinking I’m going to teach – and leave realizing I’ve been the one learning… You not only pick up new insights, but you learn how to work with character, how to listen better, and how to build trust in all directions. It’s like football with fewer shin injuries… and maybe a plate of good food on the side.”
As for how he wants to be remembered? He answers with the same clarity that has defined his ventures. “If people look back and say, ‘He built bridges where others saw borders – and he made us laugh while doing it,’ I’ll happily take that epitaph.”
Ex-con 2025
A proud milestone for GENNVAX at Africa Health Excon 2025.
This week, we took another major step toward vaccine sovereignty in Egypt and Africa.
From signing our landmark contract with Vacsera, to hosting an impactful GENNVAX session alongside Africa CDC, the Ambassadors of India and Denmark, and our global technology transfer partners — this moment reflects the power of collaboration, vision, and purpose. With a portofolio of 26 vaccines mostly locally manufactured I believe we are witnessing history in the making.
Deep thanks to UPA and its exceptional leadership, as well as the EVMA Vaccines Group, for their tireless efforts in driving forward vaccine localization across the continent.
Together, we’re not just building a facility — we’re building resilience, equity, and health security for generations to come.
The Egyptian Authority for Unified Procurement “UPA” Zydus Group AJ Vaccines Africa Health ExCon Africa CDC Gennecs Pharmaceuticals Adam ElDaba



















